Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes

Patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer are treated with trastuzumab‐based neoadjuvant therapy (NAT); some patients with residual disease post‐NAT show loss of HER2 amplification and has been inconsistently associated with oncologic outcomes.

[1]  I. Ellis,et al.  Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer , 2021, Modern Pathology.

[2]  C. O'Sullivan,et al.  Evolving standards of care and new challenges in the management of HER2‐positive breast cancer , 2020, CA: a cancer journal for clinicians.

[3]  F. Reyal,et al.  Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy , 2019, PloS one.

[4]  S. Y. Park,et al.  HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation , 2019, Journal of pathology and translational medicine.

[5]  H. Stoeger,et al.  Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy , 2019, Annals of Surgical Oncology.

[6]  L. Norton,et al.  Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy , 2019, Breast Cancer Research and Treatment.

[7]  T. Ignatov,et al.  Loss of HER2 after HER2-targeted treatment , 2019, Breast cancer research and treatment.

[8]  P. Fasching,et al.  Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.

[9]  S. André,et al.  Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer. , 2019, American journal of translational research.

[10]  A. Ozet,et al.  Receptor discordances after neoadjuvant chemotherapy and their effects on survival. , 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[11]  B. Goldacre,et al.  Catalogue of bias: publication bias , 2018, BMJ Evidence-Based Medicine.

[12]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[13]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Seigo Nakamura,et al.  Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer , 2017, Journal of surgical oncology.

[15]  H. Miyata,et al.  Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Z. Shao,et al.  Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis , 2016, Breast Cancer Research and Treatment.

[17]  Keda Yu,et al.  Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study , 2015, Oncotarget.

[18]  A. Wolff,et al.  Treatment of HER2-positive breast cancer. , 2014, Breast.

[19]  M. Dieci,et al.  Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[21]  J. Baselga,et al.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.

[22]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[23]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.